📣 VC round data is live. Check it out!
- Public Comps
- MatsukiyoCocokara
MatsukiyoCocokara Valuation Multiples
Discover revenue and EBITDA valuation multiples for MatsukiyoCocokara and similar public comparables like Tsuruha Holdings, CR Pharmaceutical, Yifeng Pharmacy, Droga Raia and more.
MatsukiyoCocokara Overview
About MatsukiyoCocokara
MatsukiyoCocokara & Co operates retail drugstores and insurance dispensing pharmacies in Japan. The company's main segments are the Matsumotokiyoshi Group Business, focused on stores under the Matsumotokiyoshi brand; the Cocokara Fine Group Business, centered on Cocokara Fine stores; and the Management Support Business, which procures products, oversees group operations, and manages indirect functions such as advertising and promotion. It generates the majority of its revenue from the Matsumotokiyoshi Group Business segment.
Founded
2007
HQ

Employees
27.6K
Website
Sectors
Financials (LTM)
EV
$5B
Valuation Multiples
Start free trialMatsukiyoCocokara Financials
MatsukiyoCocokara reported last 12-month revenue of $7B and EBITDA of $683M.
In the same LTM period, MatsukiyoCocokara generated $3B in gross profit, $683M in EBITDA, and $366M in net income.
Revenue (LTM)
MatsukiyoCocokara P&L
In the most recent fiscal year, MatsukiyoCocokara reported revenue of $7B and EBITDA of $706M.
MatsukiyoCocokara is profitable as of last fiscal year, with gross margin of 33%, EBITDA margin of 10%, and net margin of 5%.
Financial data powered by Morningstar, Inc.
MatsukiyoCocokara Stock Performance
MatsukiyoCocokara has current market cap of $6B, and enterprise value of $5B.
Market Cap Evolution
MatsukiyoCocokara's stock price is $14.76.
MatsukiyoCocokara share price increased by 3.4% in the last 30 days, and decreased by 19.6% in the last year.
MatsukiyoCocokara has an EPS (earnings per share) of $0.93.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5B | $6B | 0.0% | 3.4% | -9.5% | -19.6% | $0.93 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMatsukiyoCocokara Valuation Multiples
MatsukiyoCocokara trades at 0.7x EV/Revenue multiple, and 7.7x EV/EBITDA.
EV / Revenue (LTM)
MatsukiyoCocokara Financial Valuation Multiples
As of May 4, 2026, MatsukiyoCocokara has market cap of $6B and EV of $5B.
MatsukiyoCocokara has a P/E ratio of 16.0x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified MatsukiyoCocokara Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


MatsukiyoCocokara Margins & Growth Rates
MatsukiyoCocokara decreased revenue by 1% and EBITDA by 4% in the last fiscal year.
In the most recent fiscal year, MatsukiyoCocokara reported gross margin of 33%, EBITDA margin of 10%, and net margin of 5%.
MatsukiyoCocokara Margins
MatsukiyoCocokara Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
MatsukiyoCocokara Operational KPIs
MatsukiyoCocokara's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
MatsukiyoCocokara's Rule of 40 is 14% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
MatsukiyoCocokara's Rule of X is 21% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
MatsukiyoCocokara Competitors
MatsukiyoCocokara competitors include Tsuruha Holdings, CR Pharmaceutical, Yifeng Pharmacy, Droga Raia, Jointown Pharmaceutical, Clicks Group, Nahdi Medical, Sugi Holdings, DaShenLin Pharmaceutical and COSMOS Pharmaceutical.
Most MatsukiyoCocokara public comparables operate across Pharmacies.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.1x | 0.6x | 20.8x | 9.0x | |||
| 0.3x | 0.3x | 4.1x | 4.3x | |||
| 0.9x | 0.9x | 5.3x | 7.3x | |||
| 1.1x | 1.0x | 13.1x | 13.3x | |||
| 0.2x | 0.2x | 5.3x | 5.7x | |||
| 1.3x | 1.2x | 9.3x | 9.0x | |||
| 1.4x | 1.4x | 8.5x | 8.4x | |||
| 0.6x | 0.5x | 9.7x | 7.9x | |||
This data is available for Pro users. Sign up to see all MatsukiyoCocokara competitors and their valuation data. Start Free Trial | ||||||
MatsukiyoCocokara M&A Activity
MatsukiyoCocokara has acquired 1 company to date.
Last acquisition by MatsukiyoCocokara was on November 14th 2024. MatsukiyoCocokara acquired AppBrew for undisclosed valuation.
Latest Acquisitions by MatsukiyoCocokara
| Description | Tokyo-based AppBrew operates the LIPS platform, Japan's leading beauty review and social commerce site with millions of user-generated cosmetics ratings. The company supplies LIPS for BRANDS, an analytics tool tracking consumer sentiment and campaign performance for beauty firms like Shiseido and L'Oréal Japan. |
| HQ Country | |
| HQ City | Tokyo |
| Deal Date | 14 Nov 2024 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all MatsukiyoCocokara acquisitions and their M&A valuation multiples. Start Free Trial | |
MatsukiyoCocokara Investment Activity
MatsukiyoCocokara has invested in 1 company to date.
Latest investment by MatsukiyoCocokara was on February 25th 2026. MatsukiyoCocokara invested in Metagen Therapeutics in their $8M Series B round (EV/Revenue multiple of ).
Latest Investments by MatsukiyoCocokara
| Description | Metagen Therapeutics is a biotechnology company advancing drug discovery through microbiome science. Established as a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd., it focuses on developing therapeutics targeting gut microbiome imbalances. The Tokyo-based firm pipelines candidates for gastrointestinal disorders and metabolic conditions, utilizing advanced metagenomic sequencing and AI-driven analysis. Its lead program addresses irritable bowel syndrome with novel bacterial consortia. Metagen Therapeutics collaborates with academic institutions like Keio University for clinical validation and operates research facilities in Japan. |
| HQ Country | |
| HQ City | Tsuruoka |
| Deal Date | 25 Feb 2026 |
| Round | Series B |
| Raised | $8M |
| Investors | Aska Pharmaceutical; Canon Marketing Japan MIRAI Fund; Fujita Innovation Capital; Green Coin Best Investment Business Limited Liability Partnership; MatsukiyoCocokara; MEDIPAL Innovation Investment; Future Venture Capital; Nippon Venture Capital; Tokai Tokyo Investments |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all MatsukiyoCocokara investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout MatsukiyoCocokara
| When was MatsukiyoCocokara founded? | MatsukiyoCocokara was founded in 2007. |
| Where is MatsukiyoCocokara headquartered? | MatsukiyoCocokara is headquartered in Japan. |
| How many employees does MatsukiyoCocokara have? | As of today, MatsukiyoCocokara has over 27K employees. |
| Is MatsukiyoCocokara publicly listed? | Yes, MatsukiyoCocokara is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of MatsukiyoCocokara? | MatsukiyoCocokara trades under 3088 ticker. |
| When did MatsukiyoCocokara go public? | MatsukiyoCocokara went public in 2007. |
| Who are competitors of MatsukiyoCocokara? | MatsukiyoCocokara main competitors include Tsuruha Holdings, CR Pharmaceutical, Yifeng Pharmacy, Droga Raia, Jointown Pharmaceutical, Clicks Group, Nahdi Medical, Sugi Holdings, DaShenLin Pharmaceutical, COSMOS Pharmaceutical. |
| What is the current market cap of MatsukiyoCocokara? | MatsukiyoCocokara's current market cap is $6B. |
| What is the current revenue of MatsukiyoCocokara? | MatsukiyoCocokara's last 12 months revenue is $7B. |
| What is the current revenue growth of MatsukiyoCocokara? | MatsukiyoCocokara revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of MatsukiyoCocokara? | Current revenue multiple of MatsukiyoCocokara is 0.7x. |
| Is MatsukiyoCocokara profitable? | Yes, MatsukiyoCocokara is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of MatsukiyoCocokara? | MatsukiyoCocokara's last 12 months EBITDA is $683M. |
| What is MatsukiyoCocokara's EBITDA margin? | MatsukiyoCocokara's last 12 months EBITDA margin is 10%. |
| What is the current EV/EBITDA multiple of MatsukiyoCocokara? | Current EBITDA multiple of MatsukiyoCocokara is 7.7x. |
| What is the current FCF of MatsukiyoCocokara? | MatsukiyoCocokara's last 12 months FCF is $287M. |
| What is MatsukiyoCocokara's FCF margin? | MatsukiyoCocokara's last 12 months FCF margin is 4%. |
| What is the current EV/FCF multiple of MatsukiyoCocokara? | Current FCF multiple of MatsukiyoCocokara is 18.3x. |
| How many companies MatsukiyoCocokara has acquired to date? | As of May 2026, MatsukiyoCocokara has acquired 1 company. |
| What was the largest acquisition by MatsukiyoCocokara? | None of the M&A deals MatsukiyoCocokara has completed have disclosed valuations. |
| What companies MatsukiyoCocokara acquired? | MatsukiyoCocokara acquired AppBrew. |
| In how many companies MatsukiyoCocokara has invested to date? | As of May 2026, MatsukiyoCocokara has invested in 1 company. |
| What was the last MatsukiyoCocokara investment? | On 25th February 2026 MatsukiyoCocokara invested in Metagen Therapeutics, participating in a $8M Series B round, alongside Aska Pharmaceutical, Canon Marketing Japan MIRAI Fund, Fujita Innovation Capital, Green Coin Best Investment Business Limited Liability Partnership, MEDIPAL Innovation Investment, Future Venture Capital, Nippon Venture Capital, and Tokai Tokyo Investments. |
| In what companies MatsukiyoCocokara invested in? | MatsukiyoCocokara invested in Metagen Therapeutics. |
See public comps similar to MatsukiyoCocokara
Lists including MatsukiyoCocokara
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
